Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway

Biochemical Pharmacology

Volumn 78, Issue 6, 2009, Pages 573-582

  Kim, Mi Ju ^a   Kim, Hak Bong ^a   Bae, Jae Ho ^a   Lee, Jae Won ^a   Park, Soo Jung ^b   Kim, Dong Wan ^c   Park, Sang Ick ^b   Kang, Chi Dug ^a   Kim, Sun Hee ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Korea National Institute of Health   (South Korea)

^c Changwon National University   (South Korea)

Author keywords

Akt; Apoptosis; Death receptors; DMNB; DNA PKcs; TRAIL

Indexed keywords

4,5 DIMETHOXY 2 NITROBENZALDEHYDE; BENZALDEHYDE DERIVATIVE; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DNA DEPENDENT PROTEIN KINASE; PROTEIN BAD; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL STRAIN K 562; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION;

APOPTOSIS; CASPASES; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; K562 CELLS; MALE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, DEATH DOMAIN; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 67651151057     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.016     Document Type: Article

References (44)

1. Almasan A., and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14 (2003) 337-348
2. Yagita H., Takeda K., Hayakawa Y., Smyth M.J., and Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95 (2004) 777-783
3. Kruyt F.A. TRAIL and cancer therapy. Cancer Lett 263 (2008) 14-25
4. Sanlioglu A.D., Dirice E., Aydin C., Erin N., Koksoy S., and Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 5 (2005) 54
5. Dyer M.J., MacFarlane M., and Cohen G.M. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 25 (2007) 4505-4506
6. Morales J.C., Ruiz-Magana M.J., and Ruiz-Ruiz C. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition. Mol Immunol 44 (2007) 2587-2597
7. Zhang Y., and Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6 (2008) 1861-1871
8. Asakuma J., Sumitomo M., Asano T., Asano T., and Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 63 (2003) 1365-1370
9. Hietakangas V., Poukkula M., Heiskanen K.M., Karvinen J.T., Sistonen L., and Eriksson J.E. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol 23 (2003) 1278-1291
10. Syed V., Mukherjee K., and Godoy-Tundidor S. Ho SM. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. Cell Biochem 102 (2007) 442-452
11. Kim Y.H., and Lee Y.J. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem 100 (2007) 998-1009
12. MacFarlane M., Harper N., Snowden R.T., Dyer M.J., Barnett G.A., Pringle J.H., et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21 (2002) 6809-6818
13. Riccioni R., Pasquini L., Mariani G., Saulle E., Rossini A., Diverio D., et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90 (2005) 612-624
14. Cheng J., Hylander B.L., Baer M.R., Chen X., and Repasky E.A. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 5 (2006) 1844-1853
15. Chen X., Thakkar H., Tyan F., Gim S., Robinson H., Lee C., et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20 (2001) 6073-6083
16. Thakkar H., Chen X., Tyan F., Gim S., Robinson H., Lee C., et al. Pro-survival function of Akt/protein kinase B in prostate cancer cells relationship with TRAIL resistance. J Biol Chem 276 (2001) 38361-38369
17. Lane D., Robert V., Grondin R., Rancourt C., and Piche A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 121 (2007) 1227-1237
18. Dida F., Li Y., Iwao A., Deguchi T., Azuma E., and Komada Y. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. Exp Hematol 36 (2008) 1343-1353
19. Downward J. PI 3-kinase; Akt and cell survival. Semin Cell Dev Biol 15 (2004) 177-182
20. Parcellier A., Tintignac L.A., Zhuravleva E., and Hemmings B.A. PKB and the mitochondria: AKTing on apoptosis. Cell Signal 20 (2008) 21-30
21. McDunn J.E., Muenzer J.T., Rachdi L., Chang K.C., Davis C.G., Dunne W.M., et al. Peptide-mediated activation of Akt and extracellular regulated kinase signaling prevents lymphocyte apoptosis. Faseb J 22 (2008) 561-568
22. Kennedy S.G., Kandel E.S., Cross T.K., and Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19 (1999) 5800-5810
23. Scheid M.P., and Woodgett J.R. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2 (2001) 760-768
24. Feng J., Park J., Cron P., Hess D., and Hemmings B.A. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279 (2004) 41189-41196
25. Boldogh I., Roy G., Lee M.S., Bacsi A., Hazra T.K., Bhakat K.K., et al. Reduced DNA double strand breaks in chlorambucil resistant cells are related to high DNA-PKcs activity and low oxidative stress. Toxicology 193 (2003) 137-152
26. Friesen C., Uhl M., Pannicke U., Schwarz K., Miltner E., and Debatin K.M. DNA-ligase IV and DNA-protein kinase play a critical role in deficient caspases activation in apoptosis-resistant cancer cells by using doxorubicin. Mol Biol Cell 19 (2008) 3283-3289
27. Dragoi A.M., Fu X., Ivanov S., Zhang P., Sheng L., Wu D., et al. DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. Embo J 24 (2005) 779-789
28. Bozulic L., Surucu B., Hynx D., and Hemmings B.A. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30 (2008) 203-213
29. Surucu B., Bozulic L., Hynx D., Parcellier A., and Hemmings B.A. In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J Biol Chem 283 (2008) 30025-30033
30. Magrane J., Rosen K.M., Smith R.C., Walsh K., Gouras G.K., and Querfurth H.W. Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J Neurosci 25 (2005) 10960-10969
31. Durant S., and Karran P. Vanillins-a novel family of DNA-PK inhibitors. Nucleic Acids Res 31 (2003) 5501-5512
32. Rychahou P.G., Murillo C.A., and Evers B.M. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery 138 (2005) 391-397
33. Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C., et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275 (2000) 23319-23325
34. Yang J.K. FLIP as an anti-cancer therapeutic target. Yonsei Med J 49 (2008) 19-27
35. Zhang X., Jin T.G., Yang H., DeWolf W.C., Khosravi-Far R., and Olumi A.F. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64 (2004) 7086-7091
36. Dolcet X., Llobet D., Pallares J., Rue M., Comella J.X., and Matias-Guiu X. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 85 (2005) 885-894
37. Wilson T.R., McLaughlin K.M., McEwan M., Sakai H., Rogers K.M., Redmond K.M., et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 67 (2007) 5754-5762
38. Panka D.J., Mano T., Suhara T., Walsh K., and Mier J.W. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276 (2001) 6893-6896
39. Nam S.Y., Jung G.A., Hur G.C., Chung H.Y., Kim W.H., Seol D.W., et al. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94 (2003) 1066-1073
40. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
41. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006) 125-137
42. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11 (2006) 859-871
43. Srivastava R.K. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3 (2001) 535-546
44. Martelli A.M., Tazzari P.L., Tabellini G., Bortul R., Billi A.M., Manzoli L., et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 17 (2003) 1794-1805